Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1979 Mar;39(3):310–320. doi: 10.1038/bjc.1979.55

Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.

J M Brown, N Y Yu, P Workman
PMCID: PMC2009863  PMID: 465300

Abstract

Bilateral kidney ligation of mice immediately before injection of misonidazole (MIS) prolongs the plasma half-life of this radiosensitizer from about 2 h (in normal mice) to 10-11 h, similar to that in man. Kidney ligation does not, however, change the relative proportions of MIS and its O-demethylated metabolite, Ro-05-9963, for the first 12 h after MIS injection. Kidney ligation was used with the two radiosensitizers, MIS and Ro-05-9963, to investigate the influence of plasma half-life both on peak plasma levels and on the tumour/plasma ratio of sensitizer concentration in the EMT6 mouse tumour. Although the acute LD50 of Ro-05-9963 in normal mice was twice that of MIS, this apparent advantage was offset by peak tumour levels 50% or less of those achieved by equimolar injected doses of MIS. However, by comparing the plasma and tumour levels in mice in which the drug half-lives were prolonged by bilateral kidney ligation, it was concluded that the lower plasma and tumour levels of Ro-05-9963 were a result of its shorter plasma half-life, rather than of an intrinsic barrier to tumour penetration. Because of this rapid clearance, the radiosensitization produced by Ro-05-9963 was less than that produced by equimolar injected doses of MIS. As this difference did not occur in kidney-ligated mice, and hence would not be expected to occur in man, the comparison of MIS and Ro-05-9963 in mice produces an artificially low radiosensitization for Ro-05-9963 and possibly also for other compounds with short plasma half-lives. Although the short plasma half-life of Ro-05-9963 appeared to be responsible for its low peak plasma concentration, it did not produce a low tumour/plasma ratio. Within the limits of plasma nitroimidazole half-lives investigated (0.5-10 h) the tumour/plasma ratio was insensitive to plasma half-life, being 50-70% for both MIS and Ro-05-9963 in both normal and kidney-ligated mice. It is concluded that the common assumption that tumour/plasma ratios of MIS in the mouse are less than those in man is unjustified.

Full text

PDF
310

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Flockhart I. R., Smithen C. E., Stratford I. J., Wardman P., Watts M. E. Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res. 1976 Jul;67(1):9–20. [PubMed] [Google Scholar]
  2. Asquith J. C., Watts M. E., Patel K., Smithen C. E., Adams G. E. Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res. 1974 Oct;60(1):108–118. [PubMed] [Google Scholar]
  3. Brown J. M. Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro 7-0582. Radiat Res. 1975 Dec;64(3):633–647. [PubMed] [Google Scholar]
  4. Brown J. M., Yu N. Y., Cory M. J., Bicknell R. B., Taylor D. L. In vivo evaluation of the radiosensitizing and cytotoxic properties of newly synthesized electron-affinic drugs. Br J Cancer Suppl. 1978 Jun;3:206–211. [PMC free article] [PubMed] [Google Scholar]
  5. Chapman J. D., Reuvers A. P., Borsa J., Henderson J. S., Migliore R. D. Nitroheterocyclic drugs as selective radiosensitizers of hypoxic mammalian cells. Cancer Chemother Rep. 1974 Jul-Aug;58(4):559–570. [PubMed] [Google Scholar]
  6. Denekamp J., Fowler J. F. Radiosensitization of solid tumors by nitroimidazoles. Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):143–151. doi: 10.1016/0360-3016(78)90130-x. [DOI] [PubMed] [Google Scholar]
  7. Denekamp J., Michael B. D., Harris S. R. Hypoxic cell radiosensitizers: comparative tests of some electron affinic compounds using epidermal cell survival in vivo. Radiat Res. 1974 Oct;60(1):119–132. [PubMed] [Google Scholar]
  8. Dische S., Saunders M. I., Lee M. E., Adams G. E., Flockhart I. R. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977 May;35(5):567–579. doi: 10.1038/bjc.1977.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Flockhart I. R., Large P., Troup D., Malcolm S. L., Marten T. R. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. Xenobiotica. 1978 Feb;8(2):97–105. doi: 10.3109/00498257809060388. [DOI] [PubMed] [Google Scholar]
  10. Flockhart I. R., Sheldon P. W., Stratford I. J., Watts M. E. A metabolite of the 2-nitroimidazole misonidazole with radiosensitizing properties. Int J Radiat Biol Relat Stud Phys Chem Med. 1978 Jul;34(1):91–94. doi: 10.1080/09553007814550661. [DOI] [PubMed] [Google Scholar]
  11. Foster J. L., Flockhart I. R., Dische S., Gray A., Lenox-Smith I., Smithen C. E. Serum concentration measurements in man of the radiosensitizer Ro-07-0582: some preliminary results. Br J Cancer. 1975 Jun;31(6):679–683. doi: 10.1038/bjc.1975.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gray A. J., Dische S., Adams G. E., Flockhart I. R., Foster J. L. Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations. Clin Radiol. 1976 Apr;27(2):151–157. doi: 10.1016/s0009-9260(76)80137-7. [DOI] [PubMed] [Google Scholar]
  13. McNally N. J., Denekamp J., Sheldon P., Flockhart I. R., Stewart F. A. Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer. Radiat Res. 1978 Mar;73(3):568–580. [PubMed] [Google Scholar]
  14. Rauth A. M., Chin J., Marchow L., Paciga J. Testing of hypoxic cell radiosensitizers in vivo. Br J Cancer Suppl. 1978 Jun;3:202–205. [PMC free article] [PubMed] [Google Scholar]
  15. Saunders M. E., Dische S., Anderson P., Flockhart I. R. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Br J Cancer Suppl. 1978 Jun;3:268–270. [PMC free article] [PubMed] [Google Scholar]
  16. Stratford I. J., Adams G. E. The toxicity of the radiosensitizer misonidazole towards hypoxic cells in vitro: a model for mouse and man. Br J Radiol. 1978 Sep;51(609):745–746. doi: 10.1259/0007-1285-51-609-745. [DOI] [PubMed] [Google Scholar]
  17. Thomlinson R. H., Dische S., Gray A. J., Errington L. M. Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours. Clin Radiol. 1976 Apr;27(2):167–174. doi: 10.1016/s0009-9260(76)80139-0. [DOI] [PubMed] [Google Scholar]
  18. Urtasun R. C., Band P., Chapman J. D., Rabin H. R., Wilson A. F., Fryer C. G. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977 Mar;122(3):801–804. doi: 10.1148/122.3.801. [DOI] [PubMed] [Google Scholar]
  19. Urtasun R. C., Chapman J. D., Feldstein M. L., Band R. P., Rabin H. R., Wilson A. F., Marynowski B., Starreveld E., Shnitka T. Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl. 1978 Jun;3:271–275. [PMC free article] [PubMed] [Google Scholar]
  20. Wiltshire C. R., Workman P., Watson J. V., Bleehen N. M. Clinical studies with misonidazole. Br J Cancer Suppl. 1978 Jun;3:286–289. [PMC free article] [PubMed] [Google Scholar]
  21. Workman P., Little C. J., Marten T. R., Dale A. D., Ruane R. J., Flockhart I. R., Bleehen N. M. Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr. 1978 May 1;145(3):507–512. doi: 10.1016/s0378-4347(00)81386-9. [DOI] [PubMed] [Google Scholar]
  22. Workman P., Wiltshire C. R., Plowman P. N., Bleehen N. M. Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer. 1978 Dec;38(6):709–718. doi: 10.1038/bjc.1978.277. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES